- Home
- Immunology
- Respiratory
Respiratory
Despite advances in respiratory science, there remains a need for more advanced treatment options for people living with respiratory diseases. At Johnson & Johnson, we are committed to delivering transformational therapies for people living with immune-mediated inflammatory diseases.

Severe asthma
Asthma is a chronic lung disease affecting 262 million people globally across all ages, sexes, ethnicities and races. The symptoms of asthma - coughing, wheezing, and difficulty breathing - are caused by inflammation and narrowing of the airways. Genetic and environmental factors have been linked to asthma development, and triggers, such as allergens and infections, can start or worsen asthma symptoms. Severe asthma attacks can be life-threatening and may require emergency room visits and hospitalizations. While asthma can be managed by medications and avoiding triggers for most patients, there is currently no cure, and the burden of asthma on patients’ quality of life and on health resource utilization remains high.
Asthma is a chronic lung disease affecting
262 million people globally across all ages, sexes, ethnicities and races.”
See all latest respiratory news by visiting our newsroom.